MedTrace Logo

A Study Investigating [14C]-Labeled RO7269162 in Healthy Male Participants

NCT06733298 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-02-25

No results posted yet for this study

Summary

This study will investigate how RO7269162 labeled with a carbon tracer (\[14C\]) is absorbed, metabolized, and eliminated by the body after a single dose in healthy male volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

[ 14C]-labeled RO7269162

Participants will receive one oral dose of \[14C\]-labeled RO7269162.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
64 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-08
Primary Completion
2025-01-29
Completion
2025-01-29

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06733298 on ClinicalTrials.gov